Meeder Asset Management Inc. Boosts Stake in Edwards Lifesciences Corporation (EW)

Meeder Asset Management Inc. lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3,036.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,070 shares of the medical research company’s stock after acquiring an additional 2,004 shares during the quarter. Meeder Asset Management Inc.’s holdings in Edwards Lifesciences Corporation were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Sabal Trust CO increased its stake in shares of Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after acquiring an additional 14 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after acquiring an additional 14 shares during the last quarter. Alexandria Capital LLC increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after acquiring an additional 19 shares during the last quarter. M Holdings Securities Inc. increased its stake in shares of Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after acquiring an additional 62 shares during the last quarter. Finally, Veritable L.P. increased its stake in shares of Edwards Lifesciences Corporation by 1.2% in the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after acquiring an additional 71 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/29/meeder-asset-management-inc-boosts-stake-in-edwards-lifesciences-corporation-ew.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders have sold a total of 195,861 shares of company stock valued at $22,218,268 in the last ninety days. 2.13% of the stock is currently owned by insiders.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 101.92 on Friday. The company has a market cap of $21.52 billion, a PE ratio of 30.91 and a beta of 0.62. The company has a 50 day moving average of $110.49 and a 200 day moving average of $112.40. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.68 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post $3.75 earnings per share for the current fiscal year.

EW has been the topic of a number of research reports. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a report on Monday, August 28th. Barclays PLC upped their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a report on Tuesday, July 18th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and a consensus target price of $125.17.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit